Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.52 |
| ▸ | AHR | P35869 | 3/20 | 0.50 |
| ▸ | CMA1 | P23946 | 2/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408889 | 0.78 | TDP2 (0.65) | CRBNAHRCMA1EIF2AK2PDE3B | |
| SCHEMBL5843103 | 0.77 | CRBN (0.57) | CRBNAHRCMA1EIF2AK2PDE3B | |
| SCHEMBL4014709 | 0.77 | TDP2 (0.66) | CRBNAHRCMA1EIF2AK2PDE3B | |
| SCHEMBL13529011 | 0.77 | CRBN (0.61) | CRBNAHRCMA1EIF2AK2PDE3B | |
| SCHEMBL6744175 | 0.76 | PDE3B (0.76) | CRBNAHRCMA1EIF2AK2PDE3B | |
| SCHEMBL29850050 | 0.76 | PDE3B (0.76) | CRBNAHRCMA1EIF2AK2PDE3B | |
| SCHEMBL6744090 | 0.75 | KDM1A (0.51) | CRBNAHRCMA1EIF2AK2PDE3B | |
| SCHEMBL4476035 | 0.74 | AHR (0.67) | CRBNAHRCMA1EIF2AK2PDE3B | |
| SCHEMBL10711967 | 0.74 | AHR (0.67) | CRBNAHRCMA1EIF2AK2PDE3B | |
| SCHEMBL5873706 | 0.74 | TDP2 (0.70) | CRBNAHRCMA1EIF2AK2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6689806-B1 | MODULATING PROTEIN KINASES AND RELATED SIGNAL TRANSDUCTION PATHWAYS | SUGEN, INC. | 2004-02-10 | — | — | US | disclosed |
| EP-1165513-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056709-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | CRBN 3205/4885AHR 4782/4885CMA1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.